共 33 条
- [21] Effects of rofecoxib, a COX-2 selective inhibitor, in patients with Barrett's esophagus: Final results of a 6-month randomized controlled trialGASTROENTEROLOGY, 2006, 130 (04) : A182 - A183Lanas, AngelSopena, FedericoOrtego, JavierBarrio, EvaBujanda, LuisCosme, AngelParra, AdolfoAlcedo, JavierFerrandez, AngelBajador, EduardoPique, Josep M.
- [22] Loss of blood pressure control and rates of edema in older treated hypertensive patients following administration of the COX-2 specific inhibitors celecoxib vs. rofecoxibJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (02) : 261A - 261AWhite, WBWhelton, ABello, AEFort, JG
- [23] Upper gastrointestinal (UGI) tolerability of valdecoxib, a COX-2 specific inhibitor, compared with nonspecific NSAIDs among patients with osteoarthritis and rheumatoid arthritisANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 278 - 279Goldstein, JLEisen, GHanna, DBBurke, T
- [24] Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs -: A 6-week and a 1-year trial in patients with osteoarthritisARCHIVES OF FAMILY MEDICINE, 2000, 9 (10) : 1124 - 1134Saag, Kvan der Heijde, DFisher, CSamara, ADeTora, LBolognese, JSperling, RDaniels, B
- [25] Valdecoxib, a novel COX-2 specific inhibitor, is safe and well tolerated in elderly osteoarthritis (OA) and rheumatoid arthritis (RA) patients.JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2002, 50 (04) : S144 - S145Recker, DPKent, JDHounslow, NLau, W
- [26] A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patientsCLINICAL CANCER RESEARCH, 2003, 9 (13) : 4756 - 4760Higuchi, TIwama, TYoshinaga, KToyooka, MTaketo, MMSugihara, K
- [27] MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis (OA) in a 6-week controlled clinical trial.ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S196 - S196Saag, KFisher, CMcKay, JEhric, EZhao, PLBolognese, JSeidenberg, BDaniels, B
- [28] NONSTEROIDAL ANTI-INFLAMMATORY DRUGS HAD SYNERGISTIC EFFECT ON BONE MINERAL DENSITY IN BISPHOSPHONATE TREATMENT OSTEOARTHRITIS PATIENTS, COMPARED TO COX-2 INHIBITOROSTEOPOROSIS INTERNATIONAL, 2015, 26 : S146 - S146Lee, S. W.Chung, W. T.Lee, S. Y.Kim, J. S.
- [29] NONSTEROIDAL ANTI-INFLAMMATORY DRUGS HAD SYNERGISTIC EFFECT ON BONE MINERAL DENSITY IN BISPHOSPHONATE TREATMENT OSTEOARTHRITIS PATIENTS, COMPARED TO COX-2 INHIBITORANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1193 - 1194Lee, S. Y.Chung, W. T.Lee, S. W.
- [30] Upper gastrointestinal (UGI) tolerability of valdecoxib, A Cox-2 specific inhibitor, compared with nonspecific (NS) NSAIDs among patients with osteoarthritis (OA) and rheumatoid arthritis (RA)GASTROENTEROLOGY, 2003, 124 (04) : A511 - A512Goldstein, JLEisen, GMHanna, DBBurke, T